bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 2 from Lipid Catabolism via CPT1 as a Therapeutic Target for Prostate Cancer
Authors: Schlaepfer Isabel R. , Rider Leah , Rodrigues Lindsey Ulkus , Gijón Miguel A. , Pac Colton T. , Romero Lina , Cimic Adela , Sirintrapun S. Joseph , Glodé L. Michael , Eckel Robert H. , Cramer Scott D.
Published: April 2023

Supplementary figure 2: Additional human Prostate-derived patient-matched cell lines exposed to metabolic inhibitors: MTS proliferation assay of patient-matched prostate-derived benign (A) and cancer (B) cells exposed to Etomoxir and/or Orlistat for 48 hours.
Supplementary Figure 4 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 4 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure S4 from Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression
Authors: Woo Jong Kyu , Kang Ju-Hee , Shin DongYun , Park Seong-Hyeok , Kang Kyungsu , Nho Chu Won , Seong Je Kyung , Lee Sang-Jin , Oh Seung Hyun
Published: April 2023

Supplementary Figure S4. Ectopic expression of AURKA or AURKB restore SiRNA or daurinol mediated growth suppression.
Supplementary Figure 2 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 2 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplementary Figure S1 from Daurinol Enhances the Efficacy of Radiotherapy in Lung Cancer via Suppression of Aurora Kinase A/B Expression
Authors: Woo Jong Kyu , Kang Ju-Hee , Shin DongYun , Park Seong-Hyeok , Kang Kyungsu , Nho Chu Won , Seong Je Kyung , Lee Sang-Jin , Oh Seung Hyun
Published: April 2023

Supplementary Figure S1. Chemical structure of daurinol
Supplementary Figure 1 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Supplementary Figure 1 from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Data Supplement from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Authors: Guzi Timothy J. , Paruch Kamil , Dwyer Michael P. , Labroli Marc , Shanahan Frances , Davis Nicole , Taricani Lorena , Wiswell Derek , Seghezzi Wolfgang , Penaflor Ervin , Bhagwat Bhagyashree , Wang Wei , Gu Danling , Hsieh Yunsheng , Lee Suining , Liu Ming , Parry David
Published: April 2023

Data Supplement from Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening
Supplemental Figures S1-S7 from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
Authors: Liu Tongxin , Sun Quanquan , Li Qi , Yang Hua , Zhang Yuqin , Wang Rong , Lin Xiaoshan , Xiao Dong , Yuan Yawei , Chen Longhua , Wang Wei
Published: April 2023

Supplemental Figures S1-S7. Supplemental Figure S1: The structures of GSK2126458 and PKI-587; Supplemental Figure S2: GSK2126458 and PKI-587 inhibit NPC proliferation by blocking PI3K/mTOR signaling; Supplemental Figure S3: GSK2126458 and PKI-587 inhibit migration and invasion of NPC cells; Supplemental Figure S4: Targeting the PI3K/mTOR pathway with GSK2156458 or PKI-587 increases the radiosensitivity of NPC cells; Supplemental Figure S5: Radiosensitization induced by the dual PI3K/mTOR inhibitors is accompanied by persistence of y-H2AX foci; Supplemental Figure S6: The combination of IR and dual PI3K/mTOR inhibitors induces cell cycle arrest in NPC cells; Supplemental Figure S7: Combination of dual inhibition of PI3K/mTOR and radiation therapy is an effective treatment for NPC in vivo.
Legend for Supplementary Figures from Dual PI3K/mTOR Inhibitors, GSK2126458 and PKI-587, Suppress Tumor Progression and Increase Radiosensitivity in Nasopharyngeal Carcinoma
Authors: Liu Tongxin , Sun Quanquan , Li Qi , Yang Hua , Zhang Yuqin , Wang Rong , Lin Xiaoshan , Xiao Dong , Yuan Yawei , Chen Longhua , Wang Wei
Published: April 2023

Supplementary Figure legends
Supplementary Figure 1 from Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
Authors: Toren Paul J. , Kim Soojin , Pham Steven , Mangalji Azzra , Adomat Hans , Guns Emma S. Tomlinson , Zoubeidi Amina , Moore William , Gleave Martin E.
Published: April 2023

Supplementary Figure 1: Schematic of steroid biosynthesis pathway.
Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Authors: Zeng Jun-Ying , Sharma Sharad , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF - 79K, Supplementary Table 2. Sensitivities of L3.6pl cells, CSCs+24/44/ESA and their derived polyploid cells in response to different chemotherapeutics.
Supplementary Table 1 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Authors: Zeng Jun-Ying , Sharma Sharad , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF - 73K, Supplementary Table 1. Effect of BMS-777607 and AZD1152 on changes in DNA content in L3.6pl cells and pancreatic CSCs+24/44/ESA.
Supplementary Tables S1-S9 from Severely Impaired and Dysregulated Cytochrome P450 Expression and Activities in Hepatocellular Carcinoma: Implications for Personalized Treatment in Patients
Authors: Yan Tongmeng , Lu Linlin , Xie Cong , Chen Jiamei , Peng Xiaojuan , Zhu Lijun , Wang Ying , Li Qiang , Shi Jian , Zhou Fuyuan , Hu Ming , Liu Zhongqiu
Published: April 2023

The supplementary data contain Supplementary Tables S1 to S9. Supplementary Table S1. Human Liver Donor Details and Tissue Histology Supplementary Table S2. Incubation Conditions for CYP Activity Assays Supplementary Table S3. Analytical Parameters for Activity Assays of CYPs. Supplementary Table S4. Sequences and MRM Transitions of Proteotypic Peptides for Quantifying CYP Enzymes Supplementary Table S5. Oligonucleotide PCR Primers for Human CYP Enzymes and GAPDH Supplementary Table S6. Summary of Enzyme Kinetic Parameters for Seven CYP Activities in Pooled Human Liver Microsomes. Supplementary Table S7. Summary of Seven CYP Enzymes Activities in Tumor Tissues and Pericarcinomatous Tissues of Patients with HCC Supplementary Table S8. Summary of Seven CYPs Protein Expression Levels in Tumor Tissues and Pericarcinomatous Tissues of Patients with HCC Supplementary Table S9. Summary of Seven CYPs mRNA Expression Levels in Tumor Tissues and Pericarcinomatous Tissues of Patients with HCC
Supplementary Figure Legend from Synergistic Activities of MET/RON Inhibitor BMS-777607 and mTOR Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells
Authors: Zeng Jun-Ying , Sharma Sharad , Zhou Yong-Qing , Yao Hang-Ping , Hu Xing , Zhang Ruiwen , Wang Ming-Hai
Published: April 2023

PDF - 71K, Legends for Supplementary Figures 1 through 5.
Supplementary Figure S5: Elevated ATF3 after AD and edelfosine treatments inhibits AR promoter activity in LNCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Authors: Udayakumar Thirupandiyur S. , Stoyanova Radka , Shareef Mohammed M. , Mu Zhaomei , Philip Sakhi , Burnstein Kerry L. , Pollack Alan
Published: April 2023

Androgen deprived LNCaP cells were co-transfected with 5 µg of ARE-luciferase reporter constructs, renilla luciferase and siATF3 (10 nM), followed by treatment with edelfosine (5 µM) and R1881 (5 nM). Cells were harvested and lysed after 24 hours following treatment and assayed for ARE reporter activity. Luciferase expression of each sample was measured using dual luciferase reporter gene assay system (Promega Corp., Madison, WI). The data represents the ratio between firefly/renilla luciferase activities. The mean values {plus minus} SEM of three independent experiments are shown. *p < 0.05, compared to group with R1881 alone (one way ANOVA).
Supplementary Figure S4: ATF3 represses AR transcriptional target PSA expression in LNCaP cells after AD and edelfosine treatment. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Authors: Udayakumar Thirupandiyur S. , Stoyanova Radka , Shareef Mohammed M. , Mu Zhaomei , Philip Sakhi , Burnstein Kerry L. , Pollack Alan
Published: April 2023

Parallel experiments were done with the treatment groups as in Figure 4A to study the effect of role of edelfosine and AD mediated AR transcriptional activity. Briefly, androgen deprived LNCaP cells were co-transfected with of PSA reporter constructs (3 µg/well), CMV-ATF3 (3 µg), siATF3 or control siRNA (10 nM). After 3 h incubation with DNA/lipofectin complexes, cells were refed with 2% AD medium and treated with edelfosine (5 µM) and R1881 (10 nM). PSA expression was measured in the culture supernatant after 24 hours using an enzymatic immunoassay (ELISA) kit (Calbiotech, CA, USA). The data shown represent the mean values ({plus minus} SEM) from three independent experiments. *p < 0.05, compared to R1881 alone (one way ANOVA).
Supplementary Figure S1: Edelfosine and ADT inhibits cell proliferation in VCaP cells. from Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity
Authors: Udayakumar Thirupandiyur S. , Stoyanova Radka , Shareef Mohammed M. , Mu Zhaomei , Philip Sakhi , Burnstein Kerry L. , Pollack Alan
Published: April 2023

VCaP cells were grown for 24 h in complete (A) or AD (B) medium. Cells were treated with edelfosine (1, 2.5, 5, 10 and 20 µM) with control groups receiving PBS (0.01 M) vehicle (S1A) VCaP and (S1B) VCaP + AD. Cells were monitored and cell proliferation was measured in real time by RTCA cell proliferation assay and the average cell index was shown for 72 h. Each data point is represented by its means (n = 3) {plus minus} SD.
Supplementary Figure S3. Antibody-dependent cell-mediated cytotoxicity by virus-produced trastuzumab is dependent on immune cells from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
Authors: Liikanen Ilkka , Tähtinen Siri , Guse Kilian , Gutmann Theresia , Savola Paula , Oksanen Minna , Kanerva Anna , Hemminki Akseli
Published: April 2023

To confirm that observed ADCC mediated by virus-produced trastuzumab (Fig. 3) requires immune cells, supernatants from mock or Ad5/3-Î"24-tras infected 293 cells were purified and concentrated (virus-free, antibody-containing), and then added on N87 HER2+ gastric cancer cells without human peripheral blood mononuclear cells, followed by measuring lactate dehydrogenase (LDH) release after 6 hours as in Figure 3. As expected when lacking the effect of immune cells, neither virus-produced trastuzumab, mock-treated supernatant, nor irrelevant IgG control antibody showed cell killing (LDH release) at the 6-hour timepoint. Of note, similarly treated HER2-positive N87 cells showed dose-dependent susceptibility to commercial and virus-produced trastuzumab after a longer, 6-day incubation (Supplementary Fig. S1). Maximum LDH Release reagent was used as a positive control.
Supplementary Figure S1. Trastuzumab-coding oncolytic adenovirus mediates cytotoxicity in several HER2-positive and negative cancer cell lines from Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer
Authors: Liikanen Ilkka , Tähtinen Siri , Guse Kilian , Gutmann Theresia , Savola Paula , Oksanen Minna , Kanerva Anna , Hemminki Akseli
Published: April 2023

A) Breast cancer BT-474, SKBR3, JIMT-1, and MDA-MB-436 cells, B) ovarian cancer OVCAR3, SKOV3, CaOV3, and HEY cells, and C) gastric N87, MKN-28, MKN-45 and esophageal cancer OE19 cells were treated with commercial or virus-produced trastuzumab (N87 cell line) in escalating doses (left panels), or infected with indicated viruses at increasing virus particle per cell (VP/cell) titers (right panels). Three HER2-positive (HER2+) cancer cell lines, BT-474, N87 and OE19, showed dose-dependent susceptibility to anti-HER2 antibody treatment with IC50-value at 80.3 ng/mL, 196.3 ng/mL, and 239.1 ng/mL on day 6 post-treatment, respectively. Equivalent doses of virus-produced trastuzumab purified from supernatant of Ad5/3-Î"24-tras infected 293 cells resulted in comparable cytotoxicity of HER2-positive N87 gastric cancer (C, top left, dashed line: data from identical separate experiment). Trastuzumab-coding virus Ad5/3-Î"24-tras and the oncolytic control virus Ad5/3-Î"24 showed significant cytotoxicity in all tested cancer cell lines (right panels, A-C), while non-replicating control viruses lacked efficacy. Potency of Ad5/3-Î"24-tras virus in vitro was pronounced in cell lines expressing HER2 (comparable to oncolytic control virus in BT-474, SKBR3, OVCAR3 and N87), while HER2-negative MDA-MB-436 cells were also found equally susceptible to oncolytic viruses. Importantly, both oncolytic viruses were able to mediate total cytotoxicity at the relevant 100 VP/cell titer. Of note, because Ad5/3-Î"24 lacks a transgene and its genome is therefore smaller, the virus packages more efficiently leading to a lower VP/pfu ratio (24 versus 203 in Ad5/3-Î"24-tras). Therefore cytotoxicity was also tested according to functional titers, which rendered higher potency for the recombinant Ad5/3-Î"24-tras virus (see Supplementary Fig. S2). IC50, half-maximal inhibitory concentration.
Supplemental Fig. S3. Implication of ROS in the proliferative effects of NaHS from A Fast Hydrogen Sulfide–Releasing Donor Increases the Tumor Response to Radiotherapy
Authors: De Preter Géraldine , Deriemaeker Caroline , Danhier Pierre , Brisson Lucie , Cao Pham Thanh Trang , Grégoire Vincent , Jordan Bénédicte F. , Sonveaux Pierre , Gallez Bernard
Published: April 2023

MDA-MB-231 cancer cells were incubated with vehicle (NaCl 0.9 %), 50 µM NaHS alone or pre-treated with 3 mM N-acetyl cysteine (NAC, a ROS scavenger) before NaHS exposure in the presence of different pHe values during 4 hours. Proliferation rates were compared using BrdU incorporation measurements. No change was observed when cells were treated with NAC, suggesting that ROS were not implicated in the pro or anti-proliferative effects induced by NaHS.
Supplemental Fig. S2. Effect of the experimental conditions on cancer cells viability after proliferation measurements from A Fast Hydrogen Sulfide–Releasing Donor Increases the Tumor Response to Radiotherapy
Authors: De Preter Géraldine , Deriemaeker Caroline , Danhier Pierre , Brisson Lucie , Cao Pham Thanh Trang , Grégoire Vincent , Jordan Bénédicte F. , Sonveaux Pierre , Gallez Bernard
Published: April 2023

Viability of MDA-MB-231 was measured in vitro using trypan blue exclusion after BrdU incorporation measurements. Cancer cells were treated with 50 µM NaHS or vehicle (NaCl 0.9 %) in the presence of pHe = 6.5. No significant cell death was found in any of the experimental conditions.
Supplementary Materials and Methods from Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
Authors: Osman Abdullah A. , Monroe Marcus M. , Ortega Alves Marcus V. , Patel Ameeta A. , Katsonis Panagiotis , Fitzgerald Alison L. , Neskey David M. , Frederick Mitchell J. , Woo Sang Hyeok , Caulin Carlos , Hsu Teng-Kuei , McDonald Thomas O. , Kimmel Marek , Meyn Raymond E. , Lichtarge Olivier , Myers Jeffrey N.
Published: April 2023

Determination of drug synergy by the combination-index and isobologram analyses using the CalcuSyn software.
Supplementary Figure S1 from Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
Authors: Osman Abdullah A. , Monroe Marcus M. , Ortega Alves Marcus V. , Patel Ameeta A. , Katsonis Panagiotis , Fitzgerald Alison L. , Neskey David M. , Frederick Mitchell J. , Woo Sang Hyeok , Caulin Carlos , Hsu Teng-Kuei , McDonald Thomas O. , Kimmel Marek , Meyn Raymond E. , Lichtarge Olivier , Myers Jeffrey N.
Published: April 2023

Assessment of the degree of synergy between cisplatin and MK-1775 in HN30 (wild-type TP53) and HN31 (mutant TP53) HNSCC cells respectively using the Chou and Talalay method.
Supplemental Table 1 from Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Authors: Perera Timothy P.S. , Jovcheva Eleonora , Mevellec Laurence , Vialard Jorge , De Lange Desiree , Verhulst Tinne , Paulussen Caroline , Van De Ven Kelly , King Peter , Freyne Eddy , Rees David C. , Squires Matthew , Saxty Gordon , Page Martin , Murray Christopher W. , Gilissen Ron , Ward George , Thompson Neil T. , Newell David R. , Cheng Na , Xie Liang , Yang Jennifer , Platero Suso J. , Karkera Jayaprakash D. , Moy Christopher , Angibaud Patrick , Laquerre Sylvie , Lorenzi Matthew V.
Published: April 2023

In vitro kinase inhibition by DiscoverX KinomeScan assay. For details see (19)
Supplementary Movie 4 from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

AVI - 1146KB, Supplemental Movie SM3: Molecular simulation of colchicine bound to tubulin at higher pH.
Supplementary Movie 1 from Reversible Action of Diaminothiazoles in Cancer Cells Is Implicated by the Induction of a Fast Conformational Change of Tubulin and Suppression of Microtubule Dynamics
Authors: Thomas Nisha E. , Thamkachy Reshma , Sivakumar Krishnankutty C. , Sreedevi Krishnakumar J. , Louis Xavier Lieben , Thomas Sannu A. , Kumar Rohith , Rajasekharan Kallikat N. , Cassimeris Lynne , Sengupta Suparna
Published: April 2023

AVI - 1269KB, Supplemental Movie SM1: Molecular simulation of DAT1 bound to tubulin at higher pH.
Supplementary Figure S1 from Tumor-Associated Hyaluronan Limits Efficacy of Monoclonal Antibody Therapy
Authors: Singha Netai C. , Nekoroski Tara , Zhao Chunmei , Symons Rebecca , Jiang Ping , Frost Gregory I. , Huang Zhongdong , Shepard H. Michael
Published: April 2023

Human HAS2 gene overexpression increases HA secretion.
Supplementary Table S4 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary Table S4 shows the mean Cmax values from the DRF and the single dose study.
Figure S1 from Targeting of BRM Sensitizes BRG1-Mutant Lung Cancer Cell Lines to Radiotherapy
Authors: Zernickel Erika , Sak Ali , Riaz Assad , Klein Diana , Groneberg Michael , Stuschke Martin
Published: April 2023

Restored expression of BRG1 in BRG1 deficient H1299 cells
Supplementary Figure 3 from 3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors
Authors: Onion David , Argent Richard H. , Reece-Smith Alexander M. , Craze Madeleine L. , Pineda Robert G. , Clarke Philip A. , Ratan Hari L. , Parsons Simon L. , Lobo Dileep N. , Duffy John P. , Atherton John C. , McKenzie Andrew J. , Kumari Rajendra , King Peter , Hall Brett M. , Grabowska Anna M.
Published: April 2023

Growth of NSCLC specimens in the 3D-TGA.
Figure S1 from Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture In Vitro and Reduces Bone Osteolysis In Vivo
Authors: Pan Tianhong , Martinez Mariane , Hubka Kelsea M. , Song Jian H. , Lin Song-Chang , Yu Guoyu , Lee Yu-Chen , Gallick Gary E. , Tu Shi-Ming , Harrington Daniel A. , Farach-Carson Mary C. , Lin Sue-Hwa , Satcher Robert L.
Published: April 2023

Differentiation of pre-osteoblast MC3T3-E1 cells in 3D hydrogel
Supplementary figures from Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Authors: Boukalova Stepana , Stursa Jan , Werner Lukas , Ezrova Zuzana , Cerny Jiri , Bezawork-Geleta Ayenachew , Pecinova Alena , Dong Lanfeng , Drahota Zdenek , Neuzil Jiri
Published: April 2023

Supplementary Figures 1 - 7.
Figure S4. Increased selumetinib sensitivity when dasatinib-resistant cell lines are maintained in 2μM dasatinib. from The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer
Authors: Beadnell Thomas C. , Mishall Katie M. , Zhou Qiong , Riffert Stephen M. , Wuensch Kelsey E. , Kessler Brittelle E. , Corpuz Maia L. , Jing Xia , Kim Jihye , Wang Guoliang , Tan Aik Choon , Schweppe Rebecca E.
Published: April 2023

BCPAP, SW1736, C643, Cal62 control (C), dasatinib-resistant (DR), and dasatinib-resistant cells maintained in 2μM dasatinib in response to indicated concentrations of selumetinib (μM) for 72 hours. Growth was measured by Sulforhodamine B.
Supplementary Table 1 from Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient–Derived Xenografts
Authors: Mohamed Suhaimi Nur-Afidah , Phyo Wai Min , Yap Hao Yun , Choy Sharon Heng Yee , Wei Xiaona , Choudhury Yukti , Tan Wai Jin , Tan Luke Anthony Peng Yee , Foo Roger Sik Yin , Tan Suzanne Hui San , Tiang Zenia , Wong Chin Fong , Koh Poh Koon , Tan Min-Han
Published: April 2023

List of 40 genes in next-generation sequencing (NGS) panel
Supplementary Figures 1-4; Supplementary Tables 1 & 2 from High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide
Authors: Guertin Amy D. , O'Neil Jennifer , Stoeck Alexander , Reddy Joseph A. , Cristescu Razvan , Haines Brian B. , Hinton Marlene C. , Dorton Ryan , Bloomfield Alicia , Nelson Melissa , Vetzel Marilynn , Lejnine Serguei , Nebozhyn Michael , Zhang Theresa , Loboda Andrey , Picard Kristen L. , Schmidt Emmett V. , Dussault Isabelle , Leamon Christopher P.
Published: April 2023

Supplementary Figure 1: Assessment of kidney cancer cell lines A498, 786-O, and A704 via flow cytometry revealed surface expression of P-gp in all lines; Supplementary Figure 2: 786-O and A704 cells were transduced with lentiviral FR1, and flow cytometric analysis shows increased surface FR1 expression; Supplementary Figure 3: NCI/ADR-RES or NCI/ADR-RES-FR cells with known FR levels were treated with increasing concentrations (10-9 M to 10-5 M) of vintafolide for 2 h; Supplementary Figure 4: Ovarian tumors positive for P-gp tend to express lower levels of FR; Supplementary Table 1: P-gp inhibitor elacridar reverses P-gp-mediated DAVLBH and vintafolide resistance; Supplementary Table 2: Functional multi-drug transporter efflux assay.
Supplementary Figures S1 and S2 from Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation
Authors: van de Ven Anne L. , Tangutoori Shifalika , Baldwin Paige , Qiao Ju , Gharagouzloo Codi , Seitzer Nina , Clohessy John G. , Makrigiorgos G. Mike , Cormack Robert , Pandolfi Pier Paolo , Sridhar Srinivas
Published: April 2023

Figure S1. Drug dose-dependent enhancement of γ-H2AX and Rad51 expression using NanoOlaparib; Figure S2. Representative confocal microscopy images of Rad51 and Polθ immunostaining 30 minutes following irradiation.
Supplementary Table S5 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Kinetic data derived from SPR experiments
Supplementary Figure S3 from Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017
Authors: Uitdehaag Joost C.M. , Kooijman Jeffrey J. , de Roos Jeroen A.D.M. , Prinsen Martine B.W. , Dylus Jelle , Willemsen-Seegers Nicole , Kawase Yusuke , Sawa Masaaki , de Man Jos , van Gerwen Suzanne J.C. , Buijsman Rogier C. , Zaman Guido J.R.
Published: April 2023

Complete drug response biomarker analysis of all kinase inhibitors approved for clinical use since November 2013
Figure S1 from Theranostic Radiolabeled Anti-CD20 sdAb for Targeted Radionuclide Therapy of Non-Hodgkin Lymphoma
Authors: Krasniqi Ahmet , D'Huyvetter Matthias , Xavier Catarina , Van der Jeught Kevin , Muyldermans Serge , Van Der Heyden José , Lahoutte Tony , Tavernier Jan , Devoogdt Nick
Published: April 2023

Human CD20 expression on hCD20pos B16 cells was analyzed by flow cytometry. A) 2 x 105 Daudi cells or (B) hCD20pos B16 cells were incubated with 10 µg of Rituximab for 1h at 4{degree sign}C. After washing the cells, Rituximab binding was detected by adding 1 µg of human anti-IgG1 PE mAb (clone IS11-12E4.23.20, Miltenyi Biotec) for 30 min at 4{degree sign}C. After washing, mean fluorescence intensity (MFI) was measured using a FACS Canto Flow Cytometer (BD) and analyzed with Flow Jo 7 software (Tree Star Inc., Ashland, Oregon, USA). Background controls included: unstained Daudi and hCD20pos B16 cells, and Daudi and hCD20pos B16 cells incubated with anti-HER2 Trastuzumab mAb (isotype control) and further processed as described above. C) hCD20-expression was similar for both Daudi and hCD20pos B16 cells.
Figure S7 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Authors: Couts Kasey L. , Bemis Judson , Turner Jacqueline A. , Bagby Stacey M. , Murphy Danielle , Christiansen Jason , Hintzsche Jennifer D. , Le Anh , Pitts Todd M. , Wells Keith , Applegate Allison , Amato Carol , Multani Pratik , Chow-Maneval Edna , Tentler John J. , Shellman Yiqun G. , Rioth Matthew J. , Tan Aik-Choon , Gonzalez Rene , Medina Theresa , Doebele Robert C. , Robinson William A.
Published: April 2023

Expression of ALKATI and EML4-ALK isoforms in PDX vs xenografts
Figure S4 from ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms
Authors: Couts Kasey L. , Bemis Judson , Turner Jacqueline A. , Bagby Stacey M. , Murphy Danielle , Christiansen Jason , Hintzsche Jennifer D. , Le Anh , Pitts Todd M. , Wells Keith , Applegate Allison , Amato Carol , Multani Pratik , Chow-Maneval Edna , Tentler John J. , Shellman Yiqun G. , Rioth Matthew J. , Tan Aik-Choon , Gonzalez Rene , Medina Theresa , Doebele Robert C. , Robinson William A.
Published: April 2023

Overexpression of EML4-ALK, ALKATI, and wtALK in NIH3T3
Supplementary Figure S3 from Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines
Authors: Islam Waliul , Fang Jun , Imamura Takahisa , Etrych Tomas , Subr Vladimir , Ulbrich Karel , Maeda Hiroshi
Published: April 2023

Supplementary Figure S3 shows potentiation of antitumor effect by treatment of various NO donors.
Supplementary Data from The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma
Authors: Le Moigne Ronan , Aftab Blake T. , Djakovic Stevan , Dhimolea Eugen , Valle Eduardo , Murnane Megan , King Emily M. , Soriano Ferdie , Menon Mary-Kamala , Wu Zhi Yong , Wong Stephen T. , Lee Grace J. , Yao Bing , Wiita Arun P. , Lam Christine , Rice Julie , Wang Jinhai , Chesi Marta , Bergsagel P. Leif , Kraus Marianne , Driessen Christoph , Kiss Von Soly Szerenke , Yakes F. Michael , Wustrow David , Shawver Laura , Zhou Han-Jie , Martin Thomas G. , Wolf Jeffrey L. , Mitsiades Constantine S. , Anderson Daniel J. , Rolfe Mark
Published: April 2023

Supplementary Figure S1:Effect of CB-5083 on cell growth and survival in multiple myeloma and solid tumor cell lines; Supplementary Figure S2:CB-5083 activates UPR;Supplementary Figure S3:CB-5083 transcriptional response is unique in comparison to proteasome inhibitors;Supplementary Figure S4:CB-5083 enhances the antitumor activity of proteasome inhibitors; Supplementary Figure S5: Nrf1 upregulation induced by bortezomib is inhibited by CB-5083; Supplementary Figure S6:CB-5083 demonstrates a broad activity in multiple myeloma relevant in vivo models; Supplementary Table S1: List of antibodies used in the manuscript.
Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
Authors: Chen Luxi , Yuan Yi , Kar Shreya , Kanchi Madhu M. , Arora Suruchi , Kim Ji E. , Koh Pei F. , Yousef Einas , Samy Ramar P. , Shanmugam Muthu K. , Tan Tuan Z. , Shin Sung W. , Arfuso Frank , Shen Han M. , Yang Henry , Goh Boon C. , Park Joo I. , Gaboury Louis , Lobie Peter E. , Sethi Gautam , Lim Lina H.K. , Kumar Alan P.
Published: April 2023

Supplementary Figure 5: PPARγ ligand-induced expression of ANXA1 interacts with RIP1 blocking RIP1-NEMO interaction leading to deubiquitination of RIP1.
Supplementary Figures 1-12 from A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination
Authors: Figueras Agnès , Alsina-Sanchís Elisenda , Lahiguera Álvaro , Abreu Manuel , Muinelo-Romay Laura , Moreno-Bueno Gema , Casanovas Oriol , Graupera Mariona , Matias-Guiu Xavier , Vidal August , Villanueva Alberto , Viñals Francesc
Published: April 2023

Supplementary Figure 1. Expression of CXCR4 by immunofluorescence and of mouse Cxcr4 and human CXCR7 by RT-PCR; Supplementary Figure 2. Decrease in number of CXCR4-positive cells arising from AMD3100 treatment; Supplementary Figure 3. Absence of effect of AMD3100 on fibrosis, necrosis and proliferation; Supplementary Figure 4. Inhibition of angiogenesis by AMD3100; Supplementary Figure 5. Cytometric analysis of CTCs in blood of OVA17 implanted animals; Supplementary Figure 6. Cytokeratin 19 mRNA analysis in blood from ovarian carcinoma patients; Supplementary Figure 7. CXCR4 immunostaining in SKOV-3 tumors; Supplementary Figure 8. Absence of effect of shCXCR4 expression in SKOV-3 cells proliferation and viability, but decrease of angiogenesis in tumors; Supplementary Figure 9. Cytometric analysis of CTCs in blood of SKOV-3-sh control and SKOV-3-shCXCR4 863 inoculated animals; Supplementary Figure 10. CXCR4 inhibition by shRNA expression blocks Src and ERKs activation; Supplementary Figure 11. Cytometric analysis of GFP and CXCR4 expression in cells isolated from SKOV-3 xenografts; Supplementary Figure 12. CXCR4 and E-cadherin expression in consecutive sections of OVA17 tumors
Supplementary Figures S1-S3 from Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome Amplified Breast Cancer Cells
Authors: Koo Chuay-Yeng , Giacomini Caterina , Reyes-Corral Marta , Olmos Yolanda , Tavares Ignatius A. , Marson Charles M. , Linardopoulos Spiros , Tutt Andrew N. , Morris Jonathan D.H.
Published: April 2023

Supplementary Figure S1. A-B, Compounds 43 and 63 are ATP-competitive inhibitors of TAOK1 and TAOK2 activity. A, compound 43 or B, compound 63 (0.0001-1 µM) were incubated with TAOK1 or TAOK2 and three ATP concentrations (1 µM, 15 µM or 155 µM) in in vitro kinase assays using MBP as substrate. Calculated IC50 values are presented for each TAOK when incubated in the presence of either compound and were raised by increasing the concentration of ATP (shown in µM); n = 3. C, Compound 63 does not inhibit phosphorylation and activation of JNK by TAOKs in cells. COS1 cells were cotransfected with FLAG-JNK and either pRK5-MYC (MYC-Empty Vector), pRK5-MYC-TAOK1 or pRK5-MYC-TAOK1 (K57A) (left hand side) or pRK5-MYC, MYC-TAOK2 or MYC-TAOK2 (K57A) (right hand side), and treated with compound 63 (0-60 µM) as indicated. After 24 hours FLAG-JNK was immunoprecipitated from cell lysates and bead pellets immunoblotted for FLAG-JNK-pT183/Y185 or total FLAG-JNK. Cell lysates were also immunoblotted for expression of transfected FLAG-JNK, MYC-TAOK1 or MYC-TAOK2. A representative image is shown. Supplementary Figure S2. Dividing SKBR3 and BT549 breast cancer cells exhibit supernumerary centrosomes and TAOKs are activated catalytically during mitosis. Growing MCF-10A, SKBR3 or BT549 breast cells were fixed and costained with antibodies to detect A, pericentrin (centrosomes), α-tubulin (microtubules) plus DAPI (DNA) or B, TAOK-pS181 (phosphorylated and activated TAOKs), α-tubulin plus DAPI. Representative confocal images are shown (0.3 μm step size). Scale bar: 10 µm. Supplementary Figure S3. SiRNA oligonucleotides targeting TAOK1 and/or TAOK2 inhibit protein expression. Growing MCF-10A, SKBR3 or BT549 breast cells were transfected with nontargeting siRNA (siControl) or individual oligonucleotides targeting TAOK1 (siT1-1, siT1-4) or TAOK2 (siT2-1, siT2-4) as indicated. Cell lysates were prepared and TAOK depletion confirmed by immunoblotting with TAOK1 or TAOK2 specific antibodies. Samples were normalized using antibody to detect GAPDH and representative immunoblots are shown.
Supplementary Figure 6 from Dimethyl Fumarate Controls the NRF2/DJ-1 Axis in Cancer Cells: Therapeutic Applications
Authors: Saidu Nathaniel Edward Bennett , Noé Gaëlle , Cerles Olivier , Cabel Luc , Kavian-Tessler Niloufar , Chouzenoux Sandrine , Bahuaud Mathilde , Chéreau Christiane , Nicco Carole , Leroy Karen , Borghese Bruno , Goldwasser François , Batteux Frédéric , Alexandre Jérôme
Published: April 2023

Experimental protocol for establishment of inflammation-related mouse colon carcinogenesis along with representative IHC images of NRF2 expression in mice tumor.
Supplementary Figure S4 from Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer
Authors: Duplaquet Leslie , Figeac Martin , Leprêtre Frédéric , Frandemiche Charline , Villenet Céline , Sebda Shéhérazade , Sarafan-Vasseur Nasrin , Bénozène Mélanie , Vinchent Audrey , Goormachtigh Gautier , Wicquart Laurence , Rousseau Nathalie , Beaussire Ludivine , Truant Stéphanie , Michel Pierre , Sabourin Jean-Christophe , Galateau-Sallé Françoise , Copin Marie-Christine , Zalcman Gérard , De Launoit Yvan , Fafeur Véronique , Tulasne David
Published: April 2023

Supplementary Figure S4: Quantitative measure of FGFR4 and TRKB tyrosine phosphorylation with somatic mutations in their kinase domain
Figure S4 from Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma
Authors: Panowski Siler H. , Kuo Tracy C. , Zhang Yi , Chen Amy , Geng Tao , Aschenbrenner Laura , Kamperschroer Cris , Pascua Edward , Chen Wei , Delaria Kathy , Farias Santiago , Bateman Marjorie , Dushin Russell G. , Chin Sherman M. , Van Blarcom Thomas J. , Yeung Yik Andy , Lindquist Kevin C. , Chunyk Allison G. , Kuang Bing , Han Bora , Mirsky Michael , Pardo Ingrid , Buetow Bernard , Martin Thomas G. , Wolf Jeffrey L. , Shelton David , Rajpal Arvind , Strop Pavel , Chaparro-Riggers Javier , Sasu Barbra J.
Published: April 2023

BCMA cleavable and non-cleavable ADCs are highly active against xenograft tumors.
Table S5 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
Authors: Leconet Wilhem , Liu He , Guo Ming , Le Lamer-Déchamps Sophie , Molinier Charlotte , Kim Sae , Vrlinic Tjasa , Oster Murielle , Liu Fang , Navarro Vicente , Batra Jaspreet S. , Noriega Adolfo Lopez , Grizot Sylvestre , Bander Neil H.
Published: April 2023

Blood count parameters quantification in BALB/c mice after injection of TB1/DB4
Table S3 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation
Authors: Leconet Wilhem , Liu He , Guo Ming , Le Lamer-Déchamps Sophie , Molinier Charlotte , Kim Sae , Vrlinic Tjasa , Oster Murielle , Liu Fang , Navarro Vicente , Batra Jaspreet S. , Noriega Adolfo Lopez , Grizot Sylvestre , Bander Neil H.
Published: April 2023

BiJ591 plasma concentrations measured in BALB/c mice during pK assay
Figure S5B from Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer
Authors: Liu Shuying , Li Shunqiang , Wang Bailiang , Liu Wenbin , Gagea Mihai , Chen Huiqin , Sohn Joohyuk , Parinyanitikul Napa , Primeau Tina , Do Kim-Anh , Vande Woude George F. , Mendelsohn John , Ueno Naoto T. , Mills Gordon B. , Tripathy Debu , Gonzalez-Angulo Ana M.
Published: April 2023

Effect of HGF on cell signaling
Supplemental figure 3 from Role of Dimerized C16orf74 in Aggressive Pancreatic Cancer: A Novel Therapeutic Target
Authors: Kushibiki Toshihiro , Nakamura Toru , Tsuda Masumi , Tsuchikawa Takahiro , Hontani Koji , Inoko Kazuho , Takahashi Mizuna , Asano Toshimichi , Okamura Keisuke , Murakami Soichi , Kurashima Yo , Ebihara Yuma , Noji Takehiro , Nakanishi Yoshitsugu , Tanaka Kimitaka , Maishi Nako , Sasaki Katsunori , Park Woong-Ryeon , Shichinohe Toshiaki , Hida Kyoko , Tanaka Shinya , Hirano Satoshi
Published: April 2023

Supplemental Figure 3 shows matrigel invasion assay of C16orf74 stable cell lines (Clone C16-A. C16-B. C16-C) with 11R-DB administration and no administration. In the administered group, the invasion was significantly suppressed. * P<0.05
Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Authors: Castellano Gina M. , Zeeshan Saman , Garbuzenko Olga B. , Sabaawy Hatim E. , Malhotra Jyoti , Minko Tamara , Pine Sharon R.
Published: April 2023

Supplementary Figure from Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma
Supplementary Data from Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy
Authors: Soleimani Milad , Somma Alexander , Kaoud Tamer , Goyal Ria , Bustamante Jorge , Wylie Dennis C. , Holay Nisha , Looney Agnieszka , Giri Uma , Triplett Todd , Dalby Kevin , Kowalski Jeanne , Eckhardt S. Gail , Van Den Berg Carla
Published: April 2023

Supplementary Data from Covalent JNK Inhibitor, JNK-IN-8, Suppresses Tumor Growth in Triple-Negative Breast Cancer by Activating TFEB- and TFE3-Mediated Lysosome Biogenesis and Autophagy
Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Authors: Cvrljevic Anna N. , Butt Umar , Huhtinen Kaisa , Grönroos Tove J. , Böckelman Camilla , Lassus Heini , Butzow Ralf , Haglund Caj , Kaipio Katja , Arsiola Tiina , Laajala Teemu D. , Connolly Denise C. , Ristimäki Ari , Carpen Olli , Pouwels Jeroen , Westermarck Jukka
Published: April 2023

Supplementary Figure from Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Supplementary Methods from SGN-CD228A Is an Investigational CD228-Directed Antibody–Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models
Authors: Mazahreh Rebecca , Mason Marsha L. , Gosink John J. , Olson Devra J. , Thurman Robert , Hale Christopher , Westendorf Lori , Pires Thomas A. , Leiske Christopher I. , Carlson Markus , Nguyen Liem T. , Cochran Julia H. , Okeley Nicole M. , Yumul Roma , Jin Steven , Stone Ivan J. , Sahetya Disha , Nesterova Albina , Allred Sean , Hensley Kelly M. , Hu Rachael , Lawrence Robert , Lewis Timothy S. , Sandall Sharsti
Published: April 2023

Antibody humanization, binding assays, conjugation, mass spec, additional in vivo details
Table S1-S6 from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts
Authors: Jin Ping , Li Xin , Xia Yu , Li Huayi , Li Xiaoting , Yang Zong-Yuan , Wang Zhen , Xu Cheng , Fang Tian , Zhou Dongchen , Xiong Xiaoming , Wang Si-Yuan , Xu Sen , Gao Qinglei
Published: April 2023

Supplementary table
Supplementary Figure legends from Bepotastine Sensitizes Ovarian Cancer to PARP Inhibitors through Suppressing NF-κB–Triggered SASP in Cancer-Associated Fibroblasts
Authors: Jin Ping , Li Xin , Xia Yu , Li Huayi , Li Xiaoting , Yang Zong-Yuan , Wang Zhen , Xu Cheng , Fang Tian , Zhou Dongchen , Xiong Xiaoming , Wang Si-Yuan , Xu Sen , Gao Qinglei
Published: April 2023

Supplementary Figure legends
Supplementary Figure 1 from Payload-Binding Fab Fragments Increase the Therapeutic Index of MMAE Antibody–Drug Conjugates
Authors: Bordeau Brandon M. , Nguyen Toan Duc , Polli Joseph Ryan , Chen Ping , Balthasar Joseph P.
Published: April 2023

Supplementary figure 1
Data from Targeting Notch1 and IKKα Enhanced NF-κB Activation in CD133+ Skin Cancer Stem Cells
Authors: Quan Xin Xin , Hawk Nga Voong , Chen Weiping , Coupar Jamie , Lee Steven K. , Petersen David W. , Meltzer Paul S. , Montemarano Andrew , Braun Martin , Chen Zhong , Van Waes Carter
Published: April 2023

Abstract
Cancer stem–like cells are hypothesized to be the major tumor-initiating cell population of human cutaneous squamous cell carcinoma (cSCC), but the landscape of molecular alterations underpinning their signaling and cellular phenotypes as drug targets remains undefined. In this study, we developed an experimental pipeline to isolate a highly enriched CD133+CD31−CD45−CD61−CD24− (CD133+) cell population from primary cSCC specimens by flow cytometry. The CD133+ cells show enhanced stem–like phenotypes, which were verified by spheroid and colony formation in vitro and tumor generation in vivo. Gene expression profiling of CD133+/− cells was compared and validated, and differentially expressed gene signatures and top pathways were identified. CD133+ cells expressed a repertoire of stemness and cancer-related genes, including NOTCH and NOTCH1-mediated NF-κB pathway signaling. Other cancer-related genes from WNT, growth factor receptors, PI3K/mTOR, STAT pathways, and chromatin modifiers were also identified. Pharmacologic and genetic targeting of NOTCH1, IKKα, RELA, and RELB modulated NF-κB transactivation, the CD133+ population, and cellular and stemness phenotypes. Immunofluorescent staining confirmed colocalization of CD133+ and IKKα expression in SCC tumor specimens. Our functional, genetic, and pharmacologic studies uncovered a novel linkage between NOTCH1, IKKα, and NF-κB pathway activation in maintaining the CD133+ stem SCC phenotypes. Studies investigating markers of activation and modulators of NOTCH, IKK/NF-κB, and other pathways regulating these cancer stem gene signatures could further accelerate the development of effective therapeutic strategies to treat cSCC recurrence and metastasis. Mol Cancer Ther; 17(9); 2034–48. ©2018 AACR.
Data from TRAF2 Cooperates with Focal Adhesion Signaling to Regulate Cancer Cell Susceptibility to Anoikis
Authors: da Silva Sabrina Daniela , Xu Bin , Maschietto Mariana , Marchi Fabio Albuquerque , Alkailani Maisa I. , Bijian Krikor , Xiao Dingzhang , Alaoui-Jamali Moulay A.
Published: April 2023

Abstract
TRAF2, a RING finger adaptor protein, plays an important function in tumor necrosis factor (TNF)- and TNF-like weak inducer of apoptosis (TWEAK)-dependent signaling, in particular during inflammatory and immune responses. We identified a functional interaction of TRAF2 with focal adhesion (FA) signaling involving the focal adhesion kinase (FAK) in the regulation of cell susceptibility to anoikis. Comparison of TRAF2-proficient (TRAF2+/+) versus TRAF2-deficient (TRAF2−/−), and FAK-proficient (FAK+/+) versus FAK-deficient (FAK−/−) mouse embryonic fibroblasts and their matched reconstituted cells demonstrated that TRAF2 interacts physically with the N-terminal portion of FAK and colocalizes to cell membrane protrusions. This interaction was found to be critical for promoting resistance to cell anoikis. Similar results were confirmed in the human breast cancer cell line MDA-MB-231, where TRAF2 and FAK downregulation promoted cell susceptibility to anoikis. In human breast cancer tissues, genomic analysis of The Cancer Genome Atlas database revealed coamplification of TRAF2 and FAK in breast cancer tissues with a predictive value for shorter survival, further supporting a potential role of TRAF2–FAK cooperative signaling in cancer progression.
Data from AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth
Authors: Alves Cleidson P. , Dey-Guha Ipsita , Kabraji Sheheryar , Yeh Albert C. , Talele Nilesh P. , Solé Xavier , Chowdhury Joeeta , Mino-Kenudson Mari , Loda Massimo , Sgroi Dennis , Borresen-Dale Anne-Lise , Russnes Hege G. , Ross Kenneth N. , Ramaswamy Sridhar
Published: April 2023

Abstract
Human tumor growth depends on rapidly dividing cancer cells driving population expansion. Even advanced tumors, however, contain slowly proliferating cancer cells for reasons that remain unclear. Here, we selectively disrupt the ability of rapidly proliferating cancer cells to spawn AKT1low daughter cells that are rare, slowly proliferating, tumor-initiating, and chemotherapy-resistant, using β1-integrin activation and the AKT1-E17K–mutant oncoprotein as experimental tools in vivo. Surprisingly, we find that selective depletion of AKT1low slow proliferators actually reduces the growth of a molecularly diverse panel of human cancer cell xenograft models without globally altering cell proliferation or survival in vivo. Moreover, we find that unusual cancer patients with AKT1-E17K–mutant solid tumors also fail to produce AKT1low quiescent cancer cells and that this correlates with significantly prolonged survival after adjuvant treatment compared with other patients. These findings support a model whereby human solid tumor growth depends on not only rapidly proliferating cancer cells but also on the continuous production of AKT1low slow proliferators. Mol Cancer Ther; 17(1); 254–63. ©2017 AACR.